All In Biotech

Drug Trial Radar · NCT02434328

Efficacy and Safety of RTH258 Versus Aflibercept - Study 2

A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,048 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,048

Actual

Start

Jul 28, 2015

Primary completion

Apr 5, 2017

Study completion Mar 8, 2018

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
May 5, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection (6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Conditions

  • Neovascular Age-Related Macular Degeneration
  • Choroidal Neovascularization

Interventions

  • Brolucizumab ophthalmic solutionDrug

    Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose

  • Aflibercept ophthalmic solutionDrug

    Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study EyeTime frame: Baseline, Week 48

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.